Many different tumor types have polyclonal tumor origin: Evidence and implications

Mutation Research - Reviews in Mutation Research

Volumn 659, Issue 3, 2008, Pages 232-247

  Parsons, Barbara L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Monoclonal; Somatic mutation; Tumor clonality; Tumor development; Tumor etiology; X chromosome inactivation

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADENOMA; ASTROCYTOMA; B CELL LYMPHOMA; BASAL CELL CARCINOMA; BLADDER CANCER; BLADDER CARCINOMA; BLADDER TUMOR; BRAIN CANCER; BREAST CARCINOMA; BREAST EPITHELIAL HYPERPLASIA; BREAST FIBROADENOMA; BREAST PAPILLOMA; BREAST TUMOR; CANCER RISK; CANCER THERAPY; CARCINOMA; CELL CLONE; CERVICAL SQUAMOUS CARCINOMA; CHRONIC MYELOID LEUKEMIA; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; COLON POLYP; COLON TUMOR; COMMUNITY; COMPREHENSION; CYSTOSARCOMA PHYLLOIDES; ENDOCRINE TUMOR; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESOPHAGEAL CARCINOSARCOMA; FIBROMA; GASTROINTESTINAL TUMOR; GENE MUTATION; GENITAL TRACT CANCER; GLIOMA; HEAD AND NECK TUMOR; HUMAN; HYPOPHYSIS ADENOMA; INTRADUCTAL CARCINOMA; KAPOSI SARCOMA; LEIOMYOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG ATYPICAL ADENOMATOUS HYPERPLASIA; MEDICAL LITERATURE; MENINGIOMA; MODEL; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROSARCOMA; NONHUMAN; ONCOGENE; OVARIAN SEROUS CYSTADENOMA; OVARY CARCINOMA; OVARY TUMOR; PARATHYROID ADENOMA; PAROTID GLAND PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROSTATE TUMOR; RESPIRATORY TRACT CANCER; REVIEW; RODENT; STOMACH TUMOR; THYROID ADENOMA; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; X CHROMOSOME;

ANIMALS; CELL LINEAGE; CLONE CELLS; GENETIC HETEROGENEITY; GENETIC MARKERS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; X CHROMOSOME INACTIVATION;

RODENTIA;

EID: 50049087526     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2008.05.004     Document Type: Review

References (158)

1. Heim S., Teixeira M.A.R., and Pandis N. Are some breast carcinomas polyclonal in origin?. J. Pathol. 194 (2001) 395-397
2. Going J.J. Epithelial carcinogenesis: challenging monoclonality. J. Pathol. 200 (2003) 1-3
3. Duggan B.J., Gray S.B., McKnight J.J., Watson C.J., Johnston S.R., and Williamson K.E. Oligoclonality in bladder cancer: the implication for molecular therapies. J. Urol. 171 (2004) 419-425
4. Vogelstein B., and Kinzler K.W. The Genetic Basis of Human Cancer. second ed. (2002), McGraw-Hill, New York
5. McCann J., Spingarn N.E., Kobori J., and Ames B.N. Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids. Proc. Natl. Acad. Sci. U.S.A. 72 (1975) 979-983
6. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51 (1991) 3075-3079
7. Nowell P. The clonal evolution of tumor cell populations. Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression. Science 194 (1976) 23-28
8. Fearon E., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
9. Matsumoto T., Fuji H., Arakawa A., Yamasaki S., Sonoue H., Hattori K., Kajiyama Y., Hirose S., and Tsurumaru M. Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum. Pathol. 35 (2004) 322-327
10. Backvall H., Asplund A., Gustafsson A., Sivertsson A., Lundeberg J., and Ponten F. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat. Res. 571 (2005) 65-79
11. Loeb L., Loeb K., and Anderson J. Multiple mutations and cancer. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 776-781
12. Loeb L.A. A mutator phenotype in cancer. Cancer Res. 61 (2001) 3230-3239
13. Knudson A.G. Mutation and human cancer. Adv. Cancer Res. 17 (1973) 317-352
14. Marsh D.J., and Zori R.T. Genetic insights into familial cancers-update and recent discoveries. Cancer Lett. 181 (2002) 125-164
15. Pogribny I.P., Rusyn I., and Beland F.A. Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. Environ. Mol. Mutagen. 49 (2008) 9-15
16. Calin G.A., Sevignani C., Cumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., Bullrich F., Negrini M., and Croce C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2999-3004
17. Hanahan D., and Weinberg R.B. The hallmarks of cancer. Cell 100 (2000) 57-70
18. Tan B.T., Park C.Y., Ailles L.E., and Weissman I.L. The cancer stem cell hypothesis: a work in progress. Lab. Invest. 86 (2006) 1203-1207
19. Dalerba P., Dylla S.J., Park I.-K., Liu R., Wand X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., and Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 10158-10163
20. Kumar V., Fausto N., and Abbas A. Robbins and Cotran Pathological Basis of Disease. seventh ed. (2005), Elsevier Inc., Philadelphia, PA
21. Andreef M., Goodrich W., and Koeffler P. In: Holland J.F., and Frei E.I. (Eds). Proliferation and differentiation. Cancer Medicine. seventh ed. (2006), BC Decker Inc., London, Ontario
22. Luebeck E.G., and Moolgavkar S.H. Multistage carcinogenesis and the incidence of colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15095-15100
23. Bertram J.S. The molecular biology of cancer. Mol. Aspects Med. 21 (2001) 167-223
24. Trosko J.E., Chang C.-C., Upham B.L., and Tai M.-H. Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann. N. Y. Acad. Sci. 1028 (2004) 192-201
25. Lyon M.F. Gene action in the X-chromosome of the mouse (mus musculus L.). Nature (1961) 372-373
26. Linder D., and Gartler S.M. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science 150 (1965) 67-69
27. Gale R.E., Wheadon H., Boulos P., and Linch D.C. Tissue specificity of X-chromosome inactivation patterns. Blood 83 (1994) 2899-2905
28. Wainscoat J.S., and Fey M.F. Assessment of clonality in human tumors: a review. Cancer Res. 50 (1990) 1355-1360
29. Fialkow P.J., Gartler S.M., and Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Genetics 58 (1967) 1468-1471
30. Beutler E., Collins Z., and Irwin L.E. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N. Engl. J. Med. 276 (1967) 389-391
31. Smith J.W., Townsend D.E., and Sparks R.S. Genetic variants of glucose-6-phosphate dehydrogenase in the study of carcinoma of the cervix. Cancer 28 (1971) 529-532
32. Fialkow P.J., Sagebiel R.W., Gartler S.M., and Rimoin D.L. Multiple cell origin of hereditary neurofibromas. N. Engl. J. Med. 284 (1971) 296-300
33. Hsu S.H., Luk G.D., Krush A.J., Hamilton S.R., and Hoover H.H. Multiclonal origin of polyps in Gardner syndrome. Science 221 (1983) 951-953
34. Fialkow P.J., Gartler S.M., and Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc. Natl. Acad. Sci. U.S.A. 58 (1967) 1468-1471
35. Vogelstein B., Fearon E., Hamilton S.R., and Feinberg A.P. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 227 (1985) 642-645
36. Fearon E., Hamilton S.R., and Vogelstein B. Clonal analysis of human colorectal tumors. Science 238 (1987) 193-196
37. Novelli M.R., Williamson J.A., Tomlinson I.P., Elia G., Hodgson S.V., Talbot I.C., Bodmer W.F., and Wright N.A. Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 272 (1996) 1187-1190
38. Novelli M., Cossu A., Oukrif D., Quaglia A., Lakhani S., Poulsom R., Sasieni P., Carta P., Contini M., Pasca A., Palmieri G., Bodmer W., Tanda F., and Wright N. X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 3311-3314
39. Jovanovic L., Delahunt B., McIver B., Eberhardt N.L., and Grebe S.K.G. Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution. J. Clin. Endocrinol. Metab. 88 (2003) 3284-3291
40. Fialkow P.J. Clonal origin of human tumors. Biochim. Biophys. Acta 458 (1976) 283-321
41. Going J.J., El-Monem H.M., and Craft J.A. Clonal origin of human breast cancer. J. Pathol. 194 (2001) 406-412
42. Mutter G.L., and Boynton K.A. PCR bias in amplification of androgen receptor alleles, a trinucleotide repeat marker used in clonality studies. Nucleic Acids Res. 23 (1995) 1411-1418
43. van Dijk J.P., Heuver L., Stevens-Linders E., Jansen J.H., Mensink E.J.B.M., Raymakers R.A.P., and de Witte T. Acquired skewing of lyonization remains stable for a prolonged period in healthy blood donors. Leukemia 16 (2002) 362-367
44. Jang S.J., and Mao L. Methylation patterns in human androgen receptor gene and clonality analysis. Cancer Res. 60 (2000) 864-866
45. El Kassar N., Hetet G., Briere J., and Grandchamp B. X-chromosome inactivation in healthy females: incidence of excessive lyonization with age and comparison of assays involving DNA methylation and transcript polymorphisms. Clin. Chem. 44 (1998) 61-67
46. Sakurazawa N., Tanaka N., Onda M., and Esumi H. Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res. 60 (2000) 3165-3169
47. Siu I.-M., Robinson D.R., Schwartz S., Kung H.-J., Pretlow T.G., Petersen R.B., and Pretlow T.P. The identification of monoclonality in human aberrant crypt foci. Cancer Res. 59 (1999) 63-66
48. Kuijper A., Buerger H., Simon R., Schaefer K.-L., Croonen A., Boecker W., van der Wall E., and van Diest P.J. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J. Pathol. 197 (2002) 575-581
49. Moniz S., Catarino A.L., Marques A.R., Cavaco B., Sobrinho L., and Leite V. Clonal origin of non-medullary thyroid tumours assessed by non-random X-chromosome inactivation. Eur. J. Endocrinol. 146 (2002) 27-33
50. Walsh D.S., Peacocke M., Harrington A., James W.D., and Tsou H.C. Patterns of X chromosome inactivation in sporadic basal cell carcinomas: evidence for clonality. J. Am. Acad. Dermatol. 38 (1998) 49-55
51. Merritt A.J., Gould K.A., and Dove W.F. Polyclonal structure of intestinal adenomas in APC min/+ mice with concomitant loss of Apc+ from all tumor lineages. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13927-13931
52. Kisseberth W.C., and Sandgren E.P. Polyclonal development of mouse mammary preneoplastic nodules. Cancer Res. 64 (2004) 857-863
53. Barr R.D., and Fialkow P.J. Clonal origin of chronic myelocytic leukemia. N. Engl. J. Med. 289 (1973) 307-309
54. Moore M.A.S., Ekert H., Fitzgerald M.G., and Carmichael A. Evidence for the clonal origin of chronic myeloid leukemia from a sex chromosome mosaic: clinical, cytogenetic, and marrow culture studies. Blood 43 (1974) 15-22
55. Fialkow P.J., Lisker R., Detter J., Giblett E.R., and Zavala C. 6-Phosphogluconate dehydrogenase: hemizygous manifestation in a patient with leukemia. Science 163 (1969) 194-195
56. Rastrick J.M., Fitzgerald P.H., and Gunz F.W. Direct evidence for presence of Ph-1 chromosome in erythroid cells. Br. Med. J. 1 (1968) 96-98
57. Fitzgerald P.H., Pickering A.F., and Eiby J.R. Clonal origin of the Philadelphia chromosome and chronic myeloid leukaemia: evidence from a sex chromosome mosaic. Br. J. Haematol. 21 (1971) 473-480
58. Guo A., Ponten F., Wilander E., and Ponten J. Clonality of precursors of cervical cancer and their genetical links to invasive cancer. Mod. Pathol. 13 (2000) 606-613
59. Sun H., Enomoto T., Shroyer K.R., Ozaki K., Fudita M., Ueda Y., Nakashima R., Kuragaki C., Ueda G., and Murata Y. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn. Mol. Pathol. 11 (2002) 204-211
60. Fialkow P.J., Jackson C.E., Block M.A., and Greenawald K.A. Multicellular origin of parathyroid adenomas. N. Engl. J. Med. 297 (1977) 696-698
61. Hafner C., Knuechel R., Stoehr R., and Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer 101 (2002) 1-6
62. Friedman J.M., Fialkow P.J., Greene C.L., and Weinberg M.N. Probable clonal origin of neurofibrosarcoma in a patient with hereditary neurofibromatosis. J. Natl. Cancer Inst. 69 (1982) 12891292
63. Gordon J.I. Intestinal epithelial differentiation: new insights from chimeric and transgenic mice. J. Cell Biol. 108 (1989) 1187-1194
64. Thliveris A.T., Halberg R.B., Clipson L., Dove W.F., Sullivan L.M., Washington M.K., Stanhope S., and Newton M.A. Polyclonality of familial murine adenomas: analyses of mouse chimeras with low tumor multiplicity suggest short-range interactions. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 6960-6965
65. Newton M.A., Clipson L., Thliveris A.T., and Halberg R.B. A statistical test of the hypothesis that polyclonal intestinal tumors arise by random collision of initiated clones. Biometrics 62 (2006) 1-7
66. Winton D.J., Blount M.A., and Ponder B.A. Polyclonal origin of mouse skin papillomas. Br. J. Cancer 60 (1989) 59-63
67. Reddy A.L., and Fialkow P.J. Multicellular origin of fibrosarcomas in mice induced by the chemical carcinogen 3-methylcholanthrene. J. Exp. Med. 150 (1979) 878-887
68. Clayton R.N., and Farrell W.E. Clonality of pituitary tumours: more complicated than initially envisaged?. Brain Pathol. 11 (2001) 313-327
69. Kriangkum J., Taylor B.J., Treon S.P., Mant M.J., Reiman T., Belch A.R., and Pilarski L.M. Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin. Cancer Res. 13 (2007) 2005-2013
70. Sklar J., Cleary M.L., Thielemans K., Gralow J., Warnke B.R., and Levy R. Biclonal B-cell lymphoma. N. Engl. J. Med. 311 (1984) 20-27
71. Bissell M.J., and Radisky D. Putting tumours in context. Nat. Rev. Cancer 1 (2001) 46-54
72. Chu E.H.Y., Boehnke M., Hanash S.M., Kuick R.D., Lamb B.J., Neel J.V., Niezgoda W., Pivirotto S., and Sundling G. Estimation of mutation rates based on the analysis of polypeptide constituents of cultured human lymphoblastoid cells. Genetics 119 (1988) 693-703
73. Oller A.R., Rastogi P., Morgenthaler S., and Thilly W.G. A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat. Res. 216 (1989) 149-161
74. Araten D.J., Nafa K., Pakdeesuwan K., and Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc. Natl. Acad. Sci. U.S.A. 96 (2005) 5209-5214
75. Denver D.R., Morris K., Lynch M., and Thomas W.K. High mutation rate and predominance of insertions in the Caenorhabditis elegans nuclear genome. Nature 430 (2004) 679-682
76. McKinzie P.B., Delongchamp R.R., Heflich R.H., and Parsons B.L. Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutat. Res. 489 (2001) 47-78
77. Parsons B.L., McKinzie P.B., and Heflich R.H. Allele-specific competitive blocker-PCR detection of rare base substitutions. In: Keohavong P., and Grandt S.G. (Eds). Molecular Toxicology Protocols vol. 291 (2005), Humana Press, Totowa, NJ 235-245
78. Jenkins G.J.S., Suzen H.S., Sueiro R.A., and Parry J.M. The restriction site mutation (RSM) assay. A review of the methodology development and the current status of the technique. Mutagenesis 14 (1999) 439-448
79. Yamada S., Yashiro M., Maeda K., Nishiguchi Y., and Hirakawa K. A novel high-specificity appraoch for colorectal neoplasia: detection of K-ras2 oncogene mutation in normal mucosa. Int. J. Cancer 113 (2005) 1015-1020
80. Menke M.A.O.H., Reinecke-Luthge A., Mollmann B., Kellner A., Luttges J., and Kloppel G. Detection of K-ras point mutations in the pancreas by constant denaturing gel electrophoresis using the DCode system. BioRadiations 102 (1998) 30-31
81. Keohavong P., Zhu D., Whiteside T.L., Swalsky P., Bakker A., Elder E.M., Siegrfied J.M., Srivastava S., and Finkelstein S.D. Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal. Biochem. 247 (1997) 394-403
82. Wilson V.L., Yin X., Thompson B., Wade K.R., Watkins J.P., Wei Q., and Lee W.R. Oncogenic base substitution mutations in circulating leukocytes of normal individuals. Cancer Res. 60 (2000) 1830-1834
83. Cha R.S., Zarbl H., Keohavong P., and Thilly W.G. Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. PCR Methods Appl. 2 (1992) 12-20
84. Zhu D., Keohavong P., Finkelstein S.D., Swalsky P., Bakker A., Weissfeld J., Srivastava S., and Whiteside T.L. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res. 57 (1997) 2485-2492
85. Keohavong P., Mady H.H., Gao W.M., Siegrfied J.M., Luketich J.D., and Melhem M.F. Topographic analysis of K-ras mutations in histologically normal lung tissues and tumours of lung cancer patients. Br. J. Cancer 85 (2001) 235-241
86. Dieterle C.P., Conzelmann M., Linnemann U., and Berger M.R. Detection of isolated tumor cells by polymerase chain reaction-restriction fragment length polymorphism for K-ras mutations in tissue samples of 199 colorectal cancer patients. Clin. Cancer Res. 10 (2004) 641-650
87. Parsons B., Marchant-Miros K., Verkler T., McKinzie P., Delongchamp R., Patterson T., Broadwater R., Lamps L., and Kim L. Quantification of K-RAS codon 12 GAT and GTT mutation in colon tumor and non-tumor tissue by allele-specific competitive blocker PCR. Environ. Mol. Mutagen. 577 (2006) 42
88. Sudo H., Li-Sucholeiki X.-C., Marcelino L.A., Gruhl A.N., Zarbl H., Willey J.C., and Thilly W.G. Distributions of five common point mutants in the human tracheal-bronchial epithelium. Mutat. Res. 596 (2006) 113-127
89. Jenkins G.J.S., Doak S.H., Griffiths A.P., Tofazzal N., Shah V., Baxter J.N., and Parry J.M. Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. Br. J. Cancer 88 (2003) 1271-1276
90. Kandel R., Li S.-Q., Ozcelik H., and Rohan T. p53 protein accumulation in mutations in normal and benign breast tissue. Int. J. Cancer 87 (2000) 73-78
91. Jonason A.S., Kunala S., Price G.J., Restifo R.J., Spinelli H.M., Persing J.A., Leffell D.J., Tarone R.E., and Brash D.E. Frequent clones of p53-mutant keratinocytes in normal human skin. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 14025-14029
92. Luttges J., Diederichs A., Menke M.A.O.H., Vogel I., Kremer B., and Kloppel G. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 88 (2000) 2495-2504
93. Cha R.S., Thilly W.G., and Zarbl H. N-nitroso-N-methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3749-3753
94. Parsons B.L., Beland F.A., Von Tungeln L.S., Delongchamp R.R., Fu P.P., and Heflich R.H. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol. Carcinog. 42 (2005) 193-201
95. McKinzie P.B., Delongchamp R.R., Chen T., and Parsons B.L. ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue rats treated with N-hydroxy-2-acetylaminofluorene. Mutagenesis 21 (2006) 391-397
96. Verkler T.L., Delongchamp R.R., Miller B.J., Webb P.J., Howard P.C., and Parsons B.L. Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: a dose-response assessment. Mol. Carcinog. 47 (2008) 599-607
97. McKinzie P.B., Delongchamp R.R., and Parsons B.L. Accumulation of K-Ras mutation in rat colon after azoxymethane exposure. Environ. Mol. Mutagen. 48 (2007) 587
98. Meng F., Knapp G., Green T., Ross J., and Parsons B. ACB-PCR Measurement of K-Ras codon 12 mutation in A/J mouse lung exposed to benzo[a]pyrene: a dose-response assessment. Environ. Mol. Mutagen. 48 (2007) 591
99. Leubeck E.G., and Moolgavkar S.H. Multistage carcinogenesis and the incidence of colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15095-15100
100. Bostick R.M. Human studies of calcium supplementation and colorectal epithelial cell proliferation. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 971-980
101. Sieben N.L., Roemen G.M.J.M., Oosting J., Fleuren G.J., van Engeland M., and Prat J. Clonal analysis favors a monoclonal origin for serous borderline tumours with peritoneal implants. J. Pathol. 210 (2006) 405-411
102. Lu J., Jiang C., Mitrenga T., Cutter G., and Thompson H.J. Pathogenetic characterization of 1-methyl-1-nitrosourea-induced mammary carcinomas in the rat. Carcinogenesis 19 (1998) 223-227
103. Fox J.C., England J., White P., Ellison G., Callaghan K., Charlesworth N.R., Hehir J., McCarthy T.L., Smith-Ravin J., Talbot I.C., Snary D., Northover J.M.A., Newton C.R., and Little S. The detection of K-ras mutations in colorectal cancer using amplification-refactory mutation system. Br. J. Cancer 77 (1998) 1267-1274
104. Keohavong P., Zhu D., Melacrinos A.C., DeMichele M.A.A., Wyeant R.J., Luketich J.D., Testa J.R., Fedder M., and Siegrifed J.M. Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Int. J. Cancer 74 (1997) 162-170
105. Keohavong P., Gao W.-M., Mady H.H., Kambour-Shakir A., and Melhem M.F. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Cancer Lett. 212 (2004) 121-130
106. Chakravarti D., Mailander P., Franzen J., Higginbotham S., Cavalieri E., and Rogan E. Detection of dibenzo[a,l]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method. Oncogene 16 (1998) 3203-3210
107. Dumaz N., van Kranen H.J., de Vries A., Berg R.J.W., Wester P.W., van Kreijl C.F., Sarasin A., Daya-Grosjean L., and de Gruijl F.R. The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis 18 (1997) 897-904
108. T.L. Verkler, R.R. Delongchamp, L.H. Couch, B.J. Miller, A. Warbritton, P.W. Mellick, P.C. Howard, B.L. Parsons, Populations of p53 codon 270 CGT to TGT mutant cells in SKH-1 mouse skin tumors induced by simulated solar light, Mol. Carcinog., submitted for publication, epub doi:10.1002/mc.20439.
109. Melnikova V.O., Pacifico A., Chimenti S., Peris K., and Ananthaswamy H.N. Fate of UVB-induced p53 mutations in SKH-hr1 mouse skin after discontinuation of irradiation: relationship to skin cancer development. Oncogene 24 (2005) 7055-7063
110. Smith G., Carey F.A., Beattie J., Wilkie M.J.V., Lightfoot T.J., Coxhead J., Garner R.C., Steele R.J.C., and Wolf C.R. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 9433-9438
111. Samowitz W.S., Slattery M.L., Sweeney C., Herrick J., Wolff R.K., and Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol. Cancer Res. 5 (2007) 165-170
112. Giaretti W., Rapallo A., Sciutto A., Macciocu B., Geido E., Hermsen M.A., Postma C., Baak J.P., Williams R.A., and Meijer G.A. Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal. Cell. Pathol. 21 (2000) 49-57
113. Pretlow T.P., Brasitus T.A., Fulton N.C., Cheyer C., and Kaplan E.L. K-ras mutations in putative preneoplastic lesions in human colon. J. Natl. Cancer Inst. 85 (1993) 2004-2007
114. Bjorheim J., Minarik M., Gaudernack G., and Ekstrom P.O. Mutation detection in KRAS exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries. Anal. Biochem. 304 (2002) 200-2005
115. Yuan P., Sun M.H., Zhang J.S., Zhu X.Z., and Shi D.R. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J. Gastroenterol. 7 (2001) 352-356
116. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., and Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 973-978
117. Niho S., Yokose T., Suzuki K., Kodama T., Nishiwaki Y., and Mukai K. Monoclonality of atypical adenomatous hyperplasia of the lung. Am. J. Pathol. 154 (1999) 249-254
118. Esteller M., Garcie A., Martinez-Palones J.M., Xercavins J., and Reventos J. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab. Invest. 76 (1997) 109-116
119. Miller D.G. On the nature of susceptibility to cancer. The Presidential address. Cancer 46 (1980) 1307
120. Armitage P., and Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 91 (2004) 1983-1989
121. Toulany M., Dittmann K., Baumann M., and Rodemann H.P. Radiosensitization of ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother. Oncol. 74 (2005) 117-129
122. Toulany M., Dittmann K., Kruger M., Baumann M., and Rodemann H.P. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of P13K-AKT pathway. Radiother. Oncol. 76 (2005) 143-150
123. Toulany M., Kasten-Pisula U., Brammer I., Wand S., Chen J., Dittmann K., Baumann M., Dikomey E., and Rodemann H.P. Blockage of epidermal growth factor receptor-phospphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin. Cancer Res. 12 (2006) 4119-4126
124. Andrews G.A., Xi S., Pomerantz R.G., Lin C.J., Gooding W.E., Wentzel A.L., Wu L., Sidransky D., and Grandis J.R. Mutation of p53 in head and neck squamous cell carcinoma correlates with BCL-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26 (2004) 870-877
125. Lievre A., Bachet J.-B., Le Corre D., Boige V., Landi B., Emile J.-F., Cote J.-F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., and Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66 (2006) 3992-3995
126. Mutter G.L., Chaponot M.L., and Fletcher J.A. A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am. J. Pathol. 146 (1995) 501-508
127. Nomura S., Kaminishi M., Sugiyama K., Oohara T., and Esumi H. Clonal analysis of normal glands and intestinal metaphastic glands of stomach. In: Tahara E., Sigumachi K., and Oohara T. (Eds). Recent Advances in Gastroenterological Carcinogenesis I (1996), Monduzzi Editore S.p.A, Bologna 327-331
128. Nomura S., Kaminishi M., Sugiyama K., Oohara T., and Esumi H. Clonal analysis of isolated intestinal metaplastic glands of stomach using X linked polymorphism. Gut 42 (1998) 663-668
129. Daschner K., Assum G., Eisenbarth I., Krone W., Hoffmeyer S., Wortmann S., Heyman B., and Kehrer-Sawatzki H. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene. Biochem. Biophys. Res. Commun. 234 (1997) 346-350
130. Lee J.-H., Han S.-S., Oh H.-S., Choi Y.-D., Kim H.-J., Lee K.-H., Nam J.-H., Choi C., and Juhng S.-W. Clonal analysis of neurofibroma by PCR amplification of HUMARA gene. Korean J. Pathol. 37 (2003) 421-428
131. Jacoby L.B., Pulaski K., Rouleau G.A., and Martuza R.L. Clonal analysis of human meningiomas and schwannomas. Cancer Res. 50 (1990) 6783-6786
132. Herman V., Fagin J., Gonsky R., Kovacs K., and Melmed S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71 (1990) 1427-1433
133. Zhu J., Frosch M.P., Busque L., Beggs A.H., Bashmer K., Gilliland D.G., and Black P.M. Analysis of meningiomas by methylation- and transcription-based clonality assays. Cancer Res. 55 (1995) 3865-3872
134. Wu J.K., MacGillavry M., Kessaris C., Verheul B., Adelman L.S., and Darras B.T. Clonal analysis of meningiomas. Neurosurgery 38 (1996) 1196-1201
135. Bedi G.C., Westra W.H., Gabrielson E., Koch W., and Sidransky D. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 56 (1996) 2484-2487
136. Rabkin C.S., Janz S., Lash A., Coleman A.E., Musaba E., Liotta L., Biggar R.J., and Zhuang Z. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N. Engl. J. Med. 336 (1997) 988-993
137. Gu J., Roth L.M., Younger C., Michael H., Abjul-Karim F.W., Zhang S., Ulbright T.M., Eble J.N., and Cheng L. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low alignant potential. J. Natl. Cancer Inst. 93 (2001) 1147-1152
138. Paiss T., Wohr G., Hautmann R.E., Mattfeldt T., Muller M., Haeussler J., and Vogel W. Some tumors of the bladder are polyclonal in origin. J. Urol. 167 (2002) 718-723
139. Dong Z.-Q., Pang J.C.-S., Tong C.Y.-K., Zhou L.-F., and Ng H.-K. Clonality of oligoastrobytomas. Hum. Pathol. 33 (2002) 528-535
140. Cheng E.J., Kurman R.J., Wang M., Olts R.I., Wang B.G., Berman D.M., and Shih I.-M. Molecular genetic analysis of ovarian serous cystadenomas. Lab. Invest. (2004) 84
141. Crissman J.D., Visscher D.W., and Kubus J. Image cytophotometric DNA analysis of atypical hyperplasias and intraductual carcinomas of the breast. Arch. Pathol. Lab. Med. 114 (1990) 1249-1253
142. Jacobs I.J., Kohler M.F., Wiseman R.W., Marks J.R., Whitaker R., Kerns B.A., Humphrey P., Berchuck A., Ponder B.A., and Bast R.C. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J. Natl. Cancer Inst. 84 (1992) 1793-1798
143. Walsh D.S., Tsou H.C., Harrington A., James W.D., and Peacocke M. Clonality of basal cell carcinoma-molecular analysis of an interesting case. J. Invest. Dermatol. 106 (1996) 579-582
144. Shulman O., Laitman Y., Vilan A., Leviav A., and Friedman E. Monoclonal origin of anatomically distinct basal cell carcinomas. J. Invest. Dermatol. 126 (2006) 676-679
145. Ferraris A.M., Mangerini R., Gaetani G.F., Romei C., Pinchera A., and Pacini F. Polyclonal origin of medullary carcinoma of the thyroid in multiple endocrine neoplasia. Hum. Genet. 99 (1997) 202-205
146. Guo Z., Wu F., Asplund A., Hu X., Mazurenko N., Kisseljov F., Poten J., and Wilander E. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod. Pathol. 14 (2001) 54-61
147. Cheng L., Gu J., Ulbright T.M., MacLennan G.T., Sweeney C.J., Zhang S., Sanchez K., Koch M.O., and Eble J.N. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer 94 (2002) 104-110
148. Alexander J.M., Biller B.M.K., Zervas N.T., Arnold A., and Kilbanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86 (1990) 336-340
149. Noguchi S., Aihara T., Yoshino K., Motomura K., Inaji H., Imaoka S., and Koyama H. Demonstration of monoclonal origin of human parotid gland pleomorphic adenoma. Cancer 77 (1996) 431-435
150. Wiggans R.G., Jacobson R.J., and Fialkow P.J. Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. Blood 52 (1978) 659-663
151. Sidransky D., Frost P., Von Eschenbach A., Oyasu R., Preisinger A.C., and Vogelstein B. Clonal origin of bladder cancer. N. Engl. J. Med. 326 (1992) 737-740
152. Sklar J., Cleary M.L., Thielemans K., Gralow J., Warnke R., and Levy R. Biclonal B-cell lymphoma. N. Engl. J. Med. 311 (1984) 20-27
153. Kallioneimi O.-P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA folw cytometry and evaluation of intratumor heterogeneity. Cytometry 9 (1988) 164-169
154. Fuhr J.E., Frye A., Kattine A.A., and Meter S.V. Flow cytometric determination of breast tumor heterogeneity. Cancer 67 (1990) 1401-1405
155. Dietrich C.U., Pandis N., Tiexeira M.R., Bardi G., Gerdes A.-M., Andersen J.A., and Heim S. Chromosome abnormalities in benign hyperproliferative disorders of epitheial and stromal breast tissue. Int. J. Cancer 60 (1995) 49-53
156. Bjerknes M., Cheng H., Kim H., Schnitzler M., and Gallinger S. Clonality of dysplastic epithelium in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res. 57 (1997) 355-361
157. McCarthy R.P., Zhang S., Bostwick D.G., Qian J., Eble J.N., Wang M., Lin H., and Cheng L. Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am. J. Pathol. 165 (2004) 1395-1400
158. Lien H.-C., Lin C.-W., Mao T.-L., Kuo S.-H., Hsiao C.-H., and Huang C.-S. p53 overexpression and mutation in mataplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J. Pathol. 204 (2004) 131-139